Description

CJC no DAC/Ipamorelin 10MG

We provide CJC no DAC/Ipamorelin as a 10MG combination research formulation containing 5MG of CJC no DAC and 5MG of Ipamorelin. Furthermore, this combination brings together a growth hormone-releasing hormone analog and a selective growth hormone secretagogue. Consequently, researchers can investigate complementary mechanisms involving pituitary somatotroph signaling, growth hormone release, and the broader GH–IGF-1 axis. Research on CJC-1295 analogs and ipamorelin has established distinct but interconnected mechanisms within growth-hormone research.

Key Attributes

• Brand: AvigenLab
• Product Name: CJC no DAC/Ipamorelin
• Total Quantity: 10MG
• CJC no DAC: 5MG
• Ipamorelin: 5MG
• Stated Purity: 99.1%
• Molecular Type: Peptide Combination
• CJC Component: Modified GHRH Analog
• Ipamorelin Component: Synthetic Pentapeptide
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

CJC no DAC/Ipamorelin Product Overview

We provide CJC no DAC/Ipamorelin for research involving growth hormone secretion, GHRH receptor signaling, GHS-R1a activity, pituitary regulation, and endocrine pathway interactions. Moreover, the CJC component represents a 29-amino-acid GHRH-related analog, while Ipamorelin acts through the growth hormone secretagogue receptor system. Therefore, the combination provides researchers with two distinct signaling inputs relevant to somatotroph activity.

Additionally, research has demonstrated that Ipamorelin stimulates GH release through a GHRP-like receptor while showing greater selectivity for GH release than some earlier growth hormone secretagogues. Meanwhile, CJC-1295 research has demonstrated stimulation of GH and IGF-I secretion in experimental settings.

Researchers can explore additional materials through our Online Store.

CJC no DAC/Ipamorelin Product Identification

We identify CJC no DAC/Ipamorelin through its 10MG total configuration, comprising 5MG of each peptide. Accordingly, the product provides a clearly defined combination rather than an individual peptide presentation.

Furthermore, the two components possess distinct molecular identities and receptor relationships. This distinction allows researchers to document the formulation according to its combined composition, total quantity, individual component quantities, purity designation, and vial presentation.

Product Category

We classify CJC no DAC/Ipamorelin within our research peptide collection for endocrine, growth hormone, pituitary, and receptor-signaling investigations. Moreover, the combination brings together GHRH-related and GHS-R1a-related research pathways.

CJC-related research has examined activation of the GHRH receptor and subsequent GH secretion, while Ipamorelin research has characterized selective growth hormone secretagogue activity. Consequently, the combination provides a useful research framework for examining complementary mechanisms within the GH regulatory system.

Scientific Characteristics

CJC no DAC/Ipamorelin combines two structurally distinct peptides. The CJC component relates to the 29-amino-acid GHRH framework, whereas Ipamorelin is a synthetic pentapeptide identified as Aib-His-D-2-Nal-D-Phe-Lys-NH₂.

Furthermore, Ipamorelin research demonstrates high GH-releasing potency through a GHRP-like receptor. Meanwhile, CJC-1295 research has examined sustained GH and IGF-I responses associated with GHRH analog activity. Therefore, researchers can investigate the individual and combined signaling characteristics of the two components.

Research Applications

We position CJC no DAC/Ipamorelin for research involving growth hormone secretion, GHRH receptor signaling, GHS-R1a activity, pituitary somatotroph signaling, cAMP-associated pathways, IGF-1 regulation, and endocrine physiology.

Additionally, researchers have investigated CJC-1295-related compounds for their ability to stimulate GH and IGF-I secretion. Likewise, Ipamorelin research has examined selective stimulation of GH release through GHS-R-related mechanisms. Consequently, the combination provides a defined subject for investigating complementary endocrine signaling pathways.

Nevertheless, experimental responses can vary according to biological model, peptide preparation, concentration, experimental duration, and measured endpoint. Accordingly, researchers should interpret individual findings within their specific experimental context.

Product Configuration

We provide CJC no DAC/Ipamorelin in a 10MG vial, with the label specifying 5MG CJC no DAC and 5MG Ipamorelin. Furthermore, the product carries a stated 99.1% purity designation.

Accordingly, the total quantity and individual component quantities provide straightforward reference points for laboratory inventory. Moreover, the vial format clearly distinguishes this combination from individual CJC or Ipamorelin products within our collection.

Product Features

The primary features of CJC no DAC/Ipamorelin include a 10MG total quantity, 5MG of CJC no DAC, 5MG of Ipamorelin, and 99.1% stated purity. Additionally, our product presentation identifies the material as Not For Human Use | Research Use Only.

Furthermore, the combination connects two established research areas: GHRH-mediated pituitary signaling and GHS-R1a-mediated growth hormone secretagogue activity. Consequently, researchers can examine complementary mechanisms involved in the regulation of growth hormone secretion.

Product Specifications

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than therapeutic or consumer applications.

In particular, researchers can examine the combination within experimental systems involving pituitary signaling, growth hormone secretion, GHRH receptor activity, GHS-R1a signaling, and IGF-1-related endocrine pathways. Furthermore, human research involving long-acting CJC-1295 demonstrated increases in GH and IGF-I, while earlier ipamorelin research established selective GH-secretagogue activity.

Nevertheless, research findings associated with individual components do not automatically establish equivalent effects for a specific combination formulation. Therefore, researchers should evaluate combination-specific observations according to the experimental model and methodology.

Packaging Information

We present CJC no DAC/Ipamorelin in a clearly labeled 10MG vial featuring our AvigenLab product presentation. The packaging identifies the combination as CJC no DAC/Ipamorelin (5/5MG), communicates the total 10MG quantity, and displays the stated 99.1% Purity.

Additionally, the label communicates Not For Human Use | Research Use Only. Consequently, the packaging provides straightforward product identification while supporting consistent laboratory inventory and catalog organization.

Regulatory Information

We classify CJC no DAC/Ipamorelin as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, published research concerning either component does not constitute regulatory approval for this specific AvigenLab combination.

Moreover, a recent 2026 review describes CJC-1295 without DAC and Ipamorelin among unregulated peptides marketed for modulation of the GH–IGF-1 axis and emphasizes uncertainty surrounding composition, dosing, safety, and clinical translation in such products. Consequently, our documentation focuses on molecular characteristics and research relevance rather than presenting experimental observations as established therapeutic outcomes.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters.

Furthermore, researchers should maintain appropriate laboratory handling practices and follow the product-specific documentation associated with the material. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our 10MG presentation provides a defined combination research formulation containing 5MG CJC no DAC and 5MG Ipamorelin. The product quantity, individual component quantities, stated purity, vial format, and Research Use Only classification create clear reference points for laboratory inventory.

Moreover, both components have established research histories within endocrine and neuroendocrine science. CJC-related research has examined GHRH receptor activity and GH/IGF-I secretion, while Ipamorelin research has characterized selective growth hormone secretagogue activity.

Product Reference

Our CJC no DAC/Ipamorelin 10MG presentation provides a defined combination of 5MG CJC no DAC and 5MG Ipamorelin with a stated 99.1% purity designation. We document the formulation according to its component identities, quantities, peptide characteristics, vial configuration, and Research Use Only classification.

Consequently, the product provides researchers with a clearly identified combination for investigating GHRH-related signaling, GHS-R1a activity, pituitary somatotroph responses, growth hormone secretion, and IGF-1-axis research. Furthermore, the distinct mechanisms associated with the two components provide a useful framework for studying complementary endocrine signaling pathways under controlled research conditions.